# Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib

> **NCT01524848** · PHASE2 · COMPLETED · sponsor: **Scandinavian Sarcoma Group** · enrollment: 72 (estimated)

## Conditions studied

- Gastrointestinal Stromal Tumors

## Interventions

- **DRUG:** Pazopanib

## Key facts

- **NCT ID:** NCT01524848
- **Lead sponsor:** Scandinavian Sarcoma Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02
- **Primary completion:** 2015-01
- **Final completion:** 2016-11
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2017-05-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01524848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01524848, "Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01524848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*